Do you want to read an article? Please log in or register.
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Heart Failure
Related content
COMMENTED
Heart Failure
Semaglutide in obesity-related heart failure with preserved ejection fraction and type 2 diabetes across baseline HbA(1c) levels (STEP-HFpEF DM): a prespecified analysis of heart failure and metabolic outcomes from a randomised, placebo-controlled trial
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Lancet Diabetes Endocrinol
Davies MJ, van der Meer P, Verma S, Patel S, Chinnakondepalli KM, Borlaug BA, Butler J, Kitzman DW, Shah SJ, Harring S, Salsali A, Rasmussen S, von Lewinski D, Abhayaratna W, Petrie MC, Kosiborod MN, STEP-HFpEF Trials Committees and Investigators
doi: 10.1016/S2213-8587(24)00304-8
Heart Failure
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
Lancet
Butler J, Shah SJ, Petrie MC, Borlaug BA, Abildstrøm SZ, Davies MJ, Hovingh GK, Kitzman DW, Møller DV, Verma S, Einfeldt MN, Lindegaard ML, Rasmussen S, Abhayaratna W, Ahmed FZ, Ben-Gal T, Chopra V, Ezekowitz JA, Fu M, Ito H, Lelonek M, Melenovský V, Merkely B, Núñez J, Perna E, Schou M, Senni M, Sharma K, van der Meer P, Von Lewinski D, Wolf D, Kosiborod MN, STEP-HFpEF Trial Committees and Investigators
doi: 10.1016/S0140-6736(24)00469-0
Heart Failure
Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Trials
J Am Coll Cardiol
Verma S, Butler J, Borlaug BA, Davies M, Kitzman DW, Shah SJ, Petrie MC, Barros E, Rönnbäck C, Vestergaard LS, Schou M, Ezekowitz JA, Sharma K, Patel S, Chinnakondepalli KM, Kosiborod MN, STEP-HFpEF Trial Committees and Investigators
doi: 10.1016/j.jacc.2024.06.001
Heart Failure
Implementation of guideline-recommended therapies in heart failure with reduced ejection fraction according to heart failure duration: An analysis of 55 581 patients from the Swedish Heart Failure (SwedeHF) Registry
Eur J Heart Fail
Shahim A, Linde C, Savarese G, Dahlström U, Lund LH, Hage C
doi: 10.1002/ejhf.3565
Cardiovascular Risk and Diseases
Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial
Diabetes Obes Metab
Nanna MG, Doan QV, Fabricatore A, Faurby M, Henry AD, Houshmand-Oeregaard AS, Levine A, Navar AM, Scassellati Sforzolini T, Toliver JC
doi: 10.1111/dom.16370
RECOMMENDED
Heart Failure
Association of sex with in-hospital management and outcomes of patients with heart failure: data from the REAL-HF registry: The impact of sex in patients hospitalized for heart failure
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
Am Heart J
Sanna GD, Erre GL, Cameli M, Guerra F, Pastore MC, Marini A, Campora A, Gironella P, Costamagna M, Mandoli GE, Casiraghi M, Scuteri A, Lisi M, Casu G, Deidda M, Dessalvi CC, REAL-HF investigators
doi: 10.1016/j.ahj.2024.08.018
Heart Failure
Assessing the link of malnutrition with diabetes and mortality risk in heart failure patients
ESC Heart Fail
Prokopidis K, Chen Y, Liu Y, Zhong Z, Morwani-Mangnani J, Cuthbertson DJ, Sankaranarayanan R, Lip GYH, Isanejad M
doi: 10.1002/ehf2.15263
Heart, Artery and Coronary Diseases
Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial
Eur J Heart Fail
Petrie MC, Udell JA, Anker SD, Harrington J, Jones WS, Mattheus M, Gasior T, van der Meer P, Amir O, Bahit MC, Bauersachs J, Bayes-Genis A, Chopra VK, Januzzi JL, Lopes RD, Ponikowski P, Rossello X, Schou M, Zieroth S, Brueckmann M, Sumin M, Bhatt DL, Hernandez AF, Butler J
doi: 10.1002/ejhf.3548
Heart Failure
Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial
Eur J Heart Fail
Lassen MCH, Ostrominski JW, Inzucchi SE, Claggett BL, Kulac I, Jhund P, de Boer RA, Hernandez AF, Kosiborod MN, Lam CSP, Martinez FA, Shah SJ, Desai AS, Petersson M, Langkilde AM, Docherty KF, McMurray JJV, Solomon SD, Vaduganathan M
doi: 10.1002/ejhf.3269